Aim ImmunoTech Inc. (AIM) intrinsic value & 10-year financials
Aim ImmunoTech Inc. (AIM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 0.5% a year to $88.0K, with an average return on invested capital of -93.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.17
- Market cap
- $272.1K
- Revenue (FY2025)
- $88.0K
- Revenue growth (10-yr CAGR)
- -0.5%
- ROIC (10-yr avg)
- -93.2%
- Free cash flow (FY2025)
- —
AIM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $88.0K | -$14.0M | -$8.62 | — | -13254.5% | 495.3% |
| FY2024 | $170.0K | -$17.3M | -$0.31 | -$14.9M | -11630.6% | -445.5% |
| FY2023 | $202.0K | -$29.0M | -$0.60 | — | -15800.0% | -333.6% |
| FY2022 | $141.0K | -$19.4M | -$0.40 | -$16.2M | -14129.8% | -105.2% |
| FY2021 | $135.0K | -$19.1M | — | -$14.0M | -13954.1% | -76.6% |
| FY2020 | $163.0K | -$14.4M | — | -$10.4M | -9295.7% | -74.0% |
| FY2019 | $140.0K | -$9.5M | — | -$9.1M | -8887.9% | -89.7% |
| FY2018 | $367.0K | -$9.8M | — | -$10.7M | -3132.4% | -118.8% |
| FY2017 | $437.0K | -$8.3M | — | -$8.0M | -2612.4% | -90.5% |
| FY2016 | $92.0K | -$7.5M | — | -$7.5M | -15004.3% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
AIM ImmunoTech Inc. is facing top-line stagnation, with revenue contracting over the decade.
AIM ImmunoTech Inc. has historically struggled to out-earn its cost of capital, averaging just -62.0% ROIC.
AIM ImmunoTech Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, AIM ImmunoTech Inc. is modeled at -0.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-55.93 per share.